Literature DB >> 25612463

Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.

Banu Aygun1, Nicole A Mortier, Karen Kesler, Alexandre Lockhart, William H Schultz, Alan R Cohen, Ofelia Alvarez, Zora R Rogers, Janet L Kwiatkowski, Scott T Miller, Pamela Sylvestre, Rathi Iyer, Peter A Lane, Russell E Ware.   

Abstract

Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse events, all of which were grade 2. Among 23 children completing 30 months of study treatment, the net iron balance was favourable (-8·7 mg Fe/kg) with significant decrease in ferritin, although liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well-tolerated, with net iron removal in most children who completed 30 months of protocol-directed treatment.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  iron overload; liver iron; phlebotomy; sickle cell

Mesh:

Substances:

Year:  2015        PMID: 25612463      PMCID: PMC4631316          DOI: 10.1111/bjh.13280

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Authors:  Russell E Ware; Ronald W Helms
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.

Authors:  Anthea Greenway; Russell E Ware; Courtney D Thornburg
Journal:  Am J Hematol       Date:  2011-04       Impact factor: 10.047

3.  Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.

Authors:  Janet L Kwiatkowski; Alan R Cohen; Julian Garro; Ofelia Alvarez; Ramamorrthy Nagasubramanian; Sharada Sarnaik; Alexis Thompson; Gerald M Woods; William Schultz; Nicole Mortier; Peter Lane; Brigitta Mueller; Nancy Yovetich; Russell E Ware
Journal:  Am J Hematol       Date:  2011-11-25       Impact factor: 10.047

4.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.

Authors:  Russell E Ware; William H Schultz; Nancy Yovetich; Nicole A Mortier; Ofelia Alvarez; Lee Hilliard; Rathi V Iyer; Scott T Miller; Zora R Rogers; J Paul Scott; Myron Waclawiw; Ronald W Helms
Journal:  Pediatr Blood Cancer       Date:  2011-08-08       Impact factor: 3.167

5.  Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.

Authors:  R E Ware; S A Zimmerman; W H Schultz
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

6.  Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.

Authors:  E Angelucci; P Muretto; G Lucarelli; M Ripalti; D Baronciani; B Erer; M Galimberti; C Giardini; D Gaziev; P Polchi
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

Review 7.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Pediatr Clin North Am       Date:  2008-04       Impact factor: 3.278

8.  Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.

Authors:  Russell E Ware; Sherri A Zimmerman; Pamela B Sylvestre; Nicole A Mortier; Jacqueline S Davis; William R Treem; William H Schultz
Journal:  J Pediatr       Date:  2004-09       Impact factor: 4.406

9.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Authors:  Sherri A Zimmerman; William H Schultz; Jacqueline S Davis; Chrisley V Pickens; Nicole A Mortier; Thad A Howard; Russell E Ware
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

10.  Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.

Authors:  Massimo Franchini; Giorgio Gandini; Dino Veneri; Giovanna de Matteis; Francesca Federici; Pietro Solero; Giuseppe Aprili
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157

  10 in total
  11 in total

Review 1.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 2.  How we manage iron overload in sickle cell patients.

Authors:  Thomas D Coates; John C Wood
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

3.  Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.

Authors:  John C Wood; Sara Pressel; Zora R Rogers; Isaac Odame; Janet L Kwiatkowski; Margaret T Lee; William C Owen; Alan R Cohen; Timothy St Pierre; Matthew M Heeney; William H Schultz; Barry R Davis; Russell E Ware
Journal:  Am J Hematol       Date:  2015-09       Impact factor: 10.047

Review 4.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Angela E Rankine-Mullings; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2022-09-01

Review 5.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Sarah J Nevitt; Ashley P Jones; Jo Howard
Journal:  Cochrane Database Syst Rev       Date:  2017-04-20

6.  Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Authors:  Lise J Estcourt; Ruchika Kohli; Sally Hopewell; Marialena Trivella; Winfred C Wang
Journal:  Cochrane Database Syst Rev       Date:  2020-07-27

7.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Catherine Kimber; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2020-04-06

8.  Clinical applications of therapeutic phlebotomy.

Authors:  Kyung Hee Kim; Ki Young Oh
Journal:  J Blood Med       Date:  2016-07-18

9.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28

10.  Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Authors:  Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams
Journal:  Lancet       Date:  2015-12-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.